207 related articles for article (PubMed ID: 25933185)
21. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
[TBL] [Abstract][Full Text] [Related]
22. The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.
Mahalingam D; Patel S; Nuovo G; Gill G; Selvaggi G; Coffey M; Nawrocki ST
BMC Cancer; 2015 Jul; 15():513. PubMed ID: 26156229
[TBL] [Abstract][Full Text] [Related]
23. Emerging drugs in pancreatic cancer.
Ducreux M; Boige V; Malka D
Expert Opin Emerg Drugs; 2004 May; 9(1):73-89. PubMed ID: 15155137
[TBL] [Abstract][Full Text] [Related]
24. KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.
Kang YW; Lee JE; Jung KH; Son MK; Shin SM; Kim SJ; Fang Z; Yan HH; Park JH; Han B; Cheon MJ; Woo MG; Lim JH; Kim YS; Hong SS
Cancer Lett; 2018 Dec; 438():174-186. PubMed ID: 30217561
[TBL] [Abstract][Full Text] [Related]
25. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
O'Neil BH; Scott AJ; Ma WW; Cohen SJ; Aisner DL; Menter AR; Tejani MA; Cho JK; Granfortuna J; Coveler L; Olowokure OO; Baranda JC; Cusnir M; Phillip P; Boles J; Nazemzadeh R; Rarick M; Cohen DJ; Radford J; Fehrenbacher L; Bajaj R; Bathini V; Fanta P; Berlin J; McRee AJ; Maguire R; Wilhelm F; Maniar M; Jimeno A; Gomes CL; Messersmith WA
Ann Oncol; 2015 Sep; 26(9):1923-1929. PubMed ID: 26091808
[TBL] [Abstract][Full Text] [Related]
26. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
[TBL] [Abstract][Full Text] [Related]
27. New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy.
Lowery MA; O'Reilly EM
BioDrugs; 2011 Aug; 25(4):207-16. PubMed ID: 21815696
[TBL] [Abstract][Full Text] [Related]
28. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.
Karasic TB; O'Hara MH; Loaiza-Bonilla A; Reiss KA; Teitelbaum UR; Borazanci E; De Jesus-Acosta A; Redlinger C; Burrell JA; Laheru DA; Von Hoff DD; Amaravadi RK; Drebin JA; O'Dwyer PJ
JAMA Oncol; 2019 Jul; 5(7):993-998. PubMed ID: 31120501
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
30. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.
Wang JP; Wu CY; Yeh YC; Shyr YM; Wu YY; Kuo CY; Hung YP; Chen MH; Lee WP; Luo JC; Chao Y; Li CP
Oncotarget; 2015 Jul; 6(20):18162-73. PubMed ID: 26046796
[TBL] [Abstract][Full Text] [Related]
31. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
32. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
Laheru D; Shah P; Rajeshkumar NV; McAllister F; Taylor G; Goldsweig H; Le DT; Donehower R; Jimeno A; Linden S; Zhao M; Song D; Rudek MA; Hidalgo M
Invest New Drugs; 2012 Dec; 30(6):2391-9. PubMed ID: 22547163
[TBL] [Abstract][Full Text] [Related]
33. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.
Huang L; Holtzinger A; Jagan I; BeGora M; Lohse I; Ngai N; Nostro C; Wang R; Muthuswamy LB; Crawford HC; Arrowsmith C; Kalloger SE; Renouf DJ; Connor AA; Cleary S; Schaeffer DF; Roehrl M; Tsao MS; Gallinger S; Keller G; Muthuswamy SK
Nat Med; 2015 Nov; 21(11):1364-71. PubMed ID: 26501191
[TBL] [Abstract][Full Text] [Related]
34. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Ellenrieder V; König A; Seufferlein T
Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
[TBL] [Abstract][Full Text] [Related]
35. Nano-delivery of Gemcitabine Derivative as a Therapeutic Strategy in a Desmoplastic KRAS Mutant Pancreatic Cancer.
Das M; Li J; Bao M; Huang L
AAPS J; 2020 Jun; 22(4):88. PubMed ID: 32572645
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy for advanced pancreatic cancer.
Haller DG
Int J Radiat Oncol Biol Phys; 2003; 56(4 Suppl):16-23. PubMed ID: 12826247
[TBL] [Abstract][Full Text] [Related]
37. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
38. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
Sultana A; Smith CT; Cunningham D; Starling N; Neoptolemos JP; Ghaneh P
J Clin Oncol; 2007 Jun; 25(18):2607-15. PubMed ID: 17577041
[TBL] [Abstract][Full Text] [Related]
39. Molecular and cellular mechanisms of chemoresistance in pancreatic cancer.
Adamska A; Elaskalani O; Emmanouilidi A; Kim M; Abdol Razak NB; Metharom P; Falasca M
Adv Biol Regul; 2018 May; 68():77-87. PubMed ID: 29221990
[TBL] [Abstract][Full Text] [Related]
40. Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience.
Rakhra S; Strauss JB; Robertson J; McGinn CJ; Kim T; Huang J; Blake A; Helenowski I; Hayes JP; Mulcahy M; Small W
J Gastrointest Cancer; 2016 Jun; 47(2):196-201. PubMed ID: 27112332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]